Orchid Pharma Limited
Orchid Pharma Limited, a pharmaceutical company, engages in the development, manufacture, and marketing of active pharmaceutical ingredients, bulk actives, finished dosage formulations, and nutraceuticals in India. Its active pharmaceutical ingredients product portfolio includes oral cephalosporins, injectable cephalosporins; human and veterinary products; and antibiotics, including betalactam, m… Read more
Orchid Pharma Limited (ORCHPHARMA) - Net Assets
Latest net assets as of September 2025: ₹12.74 Billion INR
Based on the latest financial reports, Orchid Pharma Limited (ORCHPHARMA) has net assets worth ₹12.74 Billion INR as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₹17.22 Billion) and total liabilities (₹4.48 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₹12.74 Billion |
| % of Total Assets | 73.97% |
| Annual Growth Rate | 5.52% |
| 5-Year Change | 94.1% |
| 10-Year Change | 2483.93% |
| Growth Volatility | 251.41 |
Orchid Pharma Limited - Net Assets Trend (2004–2025)
This chart illustrates how Orchid Pharma Limited's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Orchid Pharma Limited (2004–2025)
The table below shows the annual net assets of Orchid Pharma Limited from 2004 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | ₹12.67 Billion | +8.36% |
| 2024-03-31 | ₹11.69 Billion | +69.82% |
| 2023-03-31 | ₹6.89 Billion | +6.37% |
| 2022-03-31 | ₹6.47 Billion | -0.85% |
| 2021-03-31 | ₹6.53 Billion | -14.76% |
| 2020-03-31 | ₹7.66 Billion | +208.80% |
| 2019-03-31 | ₹-7.04 Billion | +11.08% |
| 2018-03-31 | ₹-7.92 Billion | -69.63% |
| 2017-03-31 | ₹-4.67 Billion | -1051.67% |
| 2016-03-31 | ₹490.45 Million | -85.11% |
| 2015-03-31 | ₹3.29 Billion | -13.46% |
| 2013-03-31 | ₹3.81 Billion | -67.84% |
| 2012-03-31 | ₹11.83 Billion | +10.47% |
| 2011-03-31 | ₹10.71 Billion | +14.24% |
| 2010-03-31 | ₹9.38 Billion | +47.94% |
| 2009-03-31 | ₹6.34 Billion | -4.69% |
| 2008-03-31 | ₹6.65 Billion | +37.08% |
| 2007-03-31 | ₹4.85 Billion | -37.45% |
| 2006-03-31 | ₹7.76 Billion | +68.32% |
| 2005-03-31 | ₹4.61 Billion | +12.30% |
| 2004-03-31 | ₹4.10 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Orchid Pharma Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 2077567300000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | ₹507.19 Million | 4.00% |
| Other Comprehensive Income | ₹18.89 Billion | 149.07% |
| Other Components | ₹14.05 Billion | 110.87% |
| Total Equity | ₹12.67 Billion | 100.00% |
Orchid Pharma Limited Competitors by Market Cap
The table below lists competitors of Orchid Pharma Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Husteel
KO:005010
|
$95.45 Million |
|
Mountain & I Acquisition Co Corp
NASDAQ:MCAA
|
$95.45 Million |
|
SBI
HE:SBI
|
$95.51 Million |
|
Addvalue Technologies Ltd
F:DDU
|
$95.51 Million |
|
Bald Eagle Gold Corp.
OTCQB:BADEF
|
$95.41 Million |
|
TONGDAO LIEP.GR. DL-0001
F:6WT
|
$95.40 Million |
|
Leatec Fine Ceramics Co Ltd
TWO:6127
|
$95.39 Million |
|
NexG Bhd
KLSE:5216
|
$95.36 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Orchid Pharma Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 11,694,661,000 to 12,672,854,000, a change of 978,193,000 (8.4%).
- Net income of 996,568,000 contributed positively to equity growth.
- Other comprehensive income decreased equity by 4,910,963,999.
- Other factors increased equity by 4,892,588,999.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₹996.57 Million | +7.86% |
| Other Comprehensive Income | ₹-4.91 Billion | -38.75% |
| Other Changes | ₹4.89 Billion | +38.61% |
| Total Change | ₹- | 8.36% |
Book Value vs Market Value Analysis
This analysis compares Orchid Pharma Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.16x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 6.78x to 2.16x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2004-03-31 | ₹79.81 | ₹540.85 | x |
| 2005-03-31 | ₹89.63 | ₹540.85 | x |
| 2006-03-31 | ₹127.60 | ₹540.85 | x |
| 2007-03-31 | ₹66.39 | ₹540.85 | x |
| 2008-03-31 | ₹67.94 | ₹540.85 | x |
| 2009-03-31 | ₹70.64 | ₹540.85 | x |
| 2010-03-31 | ₹105.60 | ₹540.85 | x |
| 2011-03-31 | ₹125.42 | ₹540.85 | x |
| 2012-03-31 | ₹165.58 | ₹540.85 | x |
| 2013-03-31 | ₹53.93 | ₹540.85 | x |
| 2015-03-31 | ₹42.32 | ₹540.85 | x |
| 2016-03-31 | ₹5.64 | ₹540.85 | x |
| 2017-03-31 | ₹-52.46 | ₹540.85 | x |
| 2018-03-31 | ₹-89.00 | ₹540.85 | x |
| 2019-03-31 | ₹-79.12 | ₹540.85 | x |
| 2020-03-31 | ₹86.23 | ₹540.85 | x |
| 2021-03-31 | ₹159.96 | ₹540.85 | x |
| 2022-03-31 | ₹158.61 | ₹540.85 | x |
| 2023-03-31 | ₹168.72 | ₹540.85 | x |
| 2024-03-31 | ₹241.80 | ₹540.85 | x |
| 2025-03-31 | ₹249.88 | ₹540.85 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Orchid Pharma Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 7.86%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 10.81%
- • Asset Turnover: 0.55x
- • Equity Multiplier: 1.33x
- Recent ROE (7.86%) is above the historical average (-28.93%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2004 | 6.10% | 3.74% | 0.47x | 3.48x | ₹-159.96 Million |
| 2005 | 4.79% | 3.06% | 0.40x | 3.93x | ₹-239.87 Million |
| 2006 | 7.39% | 6.12% | 0.43x | 2.80x | ₹-202.59 Million |
| 2007 | 16.19% | 8.15% | 0.33x | 5.96x | ₹300.39 Million |
| 2008 | 26.37% | 13.48% | 0.37x | 5.24x | ₹1.09 Billion |
| 2009 | -7.73% | -3.78% | 0.31x | 6.68x | ₹-1.12 Billion |
| 2010 | 36.18% | 25.25% | 0.36x | 4.02x | ₹2.45 Billion |
| 2011 | 14.61% | 8.77% | 0.44x | 3.81x | ₹492.62 Million |
| 2012 | 8.26% | 5.44% | 0.45x | 3.38x | ₹-205.76 Million |
| 2013 | -97.90% | -28.65% | 0.28x | 12.24x | ₹-4.10 Billion |
| 2015 | -39.80% | -11.26% | 0.29x | 12.33x | ₹-1.64 Billion |
| 2016 | -569.10% | -32.47% | 0.22x | 78.75x | ₹-2.84 Billion |
| 2017 | 0.00% | -62.20% | 0.24x | 0.00x | ₹-4.49 Billion |
| 2018 | 0.00% | -51.65% | 0.22x | 0.00x | ₹-2.74 Billion |
| 2019 | 0.00% | 11.57% | 0.19x | 0.00x | ₹1.40 Billion |
| 2020 | -17.11% | -27.09% | 0.33x | 1.91x | ₹-2.08 Billion |
| 2021 | -17.85% | -25.89% | 0.36x | 1.89x | ₹-1.82 Billion |
| 2022 | -0.30% | -0.35% | 0.50x | 1.72x | ₹-666.89 Million |
| 2023 | 6.73% | 6.96% | 0.54x | 1.78x | ₹-225.47 Million |
| 2024 | 7.88% | 11.25% | 0.53x | 1.33x | ₹-247.80 Million |
| 2025 | 7.86% | 10.81% | 0.55x | 1.33x | ₹-270.72 Million |
Industry Comparison
This section compares Orchid Pharma Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $17,182,683,300
- Average return on equity (ROE) among peers: 11.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Orchid Pharma Limited (ORCHPHARMA) | ₹12.74 Billion | 6.10% | 0.35x | $95.42 Million |
| Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS) | $366.97 Million | 3.51% | 2.41x | $11.49 Million |
| Aarti Pharmalabs Limited (AARTIPHARM) | $2.27 Million | -2.03% | 0.10x | $351.56 Million |
| Abbott India Limited (ABBOTINDIA) | $11.96 Billion | 21.35% | 0.35x | $1.60 Billion |
| Ajanta Pharma Limited (AJANTPHARM) | $37.90 Billion | 24.28% | 0.32x | $1.51 Billion |
| Akums Drugs and Pharmaceutical (AKUMS) | $7.20 Billion | -0.56% | 3.88x | $123.79 Million |
| Albert David Limited (ALBERTDAVD) | $1.86 Billion | 5.29% | 0.56x | $16.25 Million |
| Alivus Life Sciences Limited (ALIVUS) | $21.38 Billion | 21.84% | 0.26x | $329.34 Million |
| Alkem Laboratories Limited (ALKEM) | $88.47 Billion | 18.60% | 0.59x | $2.41 Billion |
| Alpa Laboratories Limited (ALPA) | $1.71 Billion | 11.38% | 0.30x | $5.51 Million |
| Amrutanjan Health Care Limited (AMRUTANJAN) | $964.67 Million | 9.99% | 0.49x | $81.74 Million |